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Abstract
Congenital deficiency of the mitochondrial respiratory chain complex I (CI) is a common defect of oxidative phosphorylation
(OXPHOS). Despite major advances in the biochemical and molecular diagnostics and the deciphering of CI structure,
function assembly and pathomechanism, there is currently no satisfactory cure for patients with mitochondrial complex I
defects. Small molecules provide one feasible therapeutic option, however their use has not been systematically evaluated
using a standardized experimental system. In order to evaluate potentially therapeutic compounds, we set up a relatively
simple system measuring different parameters using only a small amount of patient’s fibroblasts, in glucose free medium,
where growth is highly OXPOS dependent. Ten different compounds were screened using fibroblasts derived from seven CI
patients, harboring different mutations. 5-Aminoimidazole-4-carboxamide ribotide (AICAR) was found to be the most
beneficial compound improving growth and ATP content while decreasing ROS production. AICAR also increased
mitochondrial biogenesis without altering mitochondrial membrane potential (Dy). Fluorescence microscopy data
supported increased mitochondrial biogenesis and activation of the AMP activated protein kinase (AMPK). Other
compounds such as; bezafibrate and oltipraz were rated as favorable while polyphenolic phytochemicals (resverastrol,
grape seed extract, genistein and epigallocatechin gallate) were found not significant or detrimental. Although the results
have to be verified by more thorough investigation of additional OXPHOS parameters, preliminary rapid screening of
potential therapeutic compounds in individual patient’s fibroblasts could direct and advance personalized medical
treatment.
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Introduction
The congenital disorders of mitochondrial oxidative phosphor-
ylation (OXPHOS) are common inborn errors of metabolism,
with an incidence of 1:5000–8000 live births [1,2]. Among these,
deficiency of mitochondrial respiratory chain complex I (NADH
CoQ oxidoreductase, EC 1.6.5.3) is the most common and
accounts for one-third of all patients referred for OXPHOS
evaluation [3].
Complex I (CI), is the first complex of the mitochondrial
respiratory chain. It is a large multimeric complex composed of 45
structural subunits; seven are encoded by the mitochondrial DNA
(mtDNA) while 38 structural subunits and a number of CI
assembly factors are all nuclear encoded [4]. Some of the subunits
are post transcriptionally modified by phosphorylation, acetylation
or glutathionylation [5–7].
Disease causing mutations have been identified in all mtDNA
encoded subunits as well as in a number of the nuclear encoded
complex I subunits and assembly factors [8,9].
The clinical phenotype of complex I deficiency is varied and
includes severe neonatal lactic acidosis, Leigh disease, cardiomy-
opathy-encephalopathy, hepatopathy-tubulopathy, leukodystro-
phy with macrocephaly optic atrophy, cerebellar ataxia, retinitis
pigmentosa and growth retardation [10]. The extensive damage
observed in patients with complex I deficiency is most probably
due to energy depletion and to over- production of reactive oxygen
species (ROS) with subsequent initiation of the apoptotic cascade
[11–13].
Despite major advances in the biochemical and molecular
diagnostics and the deciphering of the CI structure, function,
assembly and pathomechanism, there is currently no satisfactory
cure for patients with mitochondrial complex I defects. Small
molecules provide one feasible therapeutic option, however their
use has not been systematically evaluated using a standardized
experimental system, and treatment has been based on ‘‘trial and
error’’ [14–16]. Vitamins (vitamin K, riboflavin, B1,B2), cofactors
(CoQ, carnitine, creatine), and ROS scavengers (vitamin E,
CoQ10), have all been administered to improve OXPHOS, by
providing alternate substrates, removing lactate accumulation (by
dichloroacetate) and ameliorating oxidative damage (reviewed by
Dimauro and Mancuso) [15–16]. The favorable effect of
Coenzyme Q10 supplementation for CoQ deficiency is undispu-
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only in a few cases of complex I deficiency [11,17]. For other
compounds, results have been equivocal or were reported
anecdotally. In recent years, a large number of compounds with
therapeutic potential have been described. These include poly-
phenolic phytochemicals such as resveratrol, grape seed extract,
green tea extract and genistein. Resveratrol is a natural
phytoalexin found in a wide variety of plant species, including
grapes. Among its numerous properties, resveratrol has been
reported to have anti-oxidant activities and to activate the genetic
expression of key genes in energy metabolism such as peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC1a). Resveratrol and grape seed extract (a proanthocyanidin)
were demonstrated to have beneficial effects on mitochondrial
function in several experimental models [18–20]. Green tea
polyphenols attenuated mitochondrial dysfunction in glucose
deprived glial cell cultures [21]. Genistein is a soy derived
isoflavone which has been evaluated in substrate reduction therapy
for mucopolysaccharidoses and was also reported to induce
mitochondrial biogenesis [22–23].
In addition to polyphenols, other substances such as compounds
enhancing energy metabolism, antioxidants and chemical chap-
erones are potentially beneficial.
Representative of this type are 5-Aminoimidazole-4-carboxa-
mide ribotide (AICAR), oltipraz, bezafibrate and sodium phenyl-
butyrate.
AICAR is a pharmacological activator of AMP activated protein
kinase (AMPK).This heterotrimeric protein complex plays a key role
inthe regulationofenergyhomeostasis.Thekinaseisactivated byan
elevated AMP/ATP ratio caused by cellular and environmental
stress, such as heat shock, hypoxia and ischemia. AMPK regulates
energy expenditure by modulating NADH
+ dependent-type III
deacetylase SIRT1, resulting in the deacetylation of downstream
targets including PGC1a forkhead box O1 and 3 transcription
factors [24]. Notably, Thr172 phosphorylation on the AMPK
protein is a prerequisite for its activation [25]. Oltipraz is a 1,2-
dithiole-3-thione compound with antioxidant properties. Oltipraz
has also been demonstrated to reduce apoptosis in cells with
chemically inhibited CI by exerting its cytoprotective effect though
AMPK[26–27].Bezafibrateisanagonistofperoxisomeproliferator-
activated receptors (PPARs) stimulating oxidative metabolism and
has a documented positive effect on mitochondria. On the other
hand, fenofibrate was reported to have a negative effect on CI
[16,28–29]. Sodium phenyl butyrate is a, histone deacetylase
(HDAC) inhibitor, affecting protein phosphorylation and relief of
endoplasmic reticulum stress. Although the mechanism of action of
this compound is poorlydefined, ithas been found to be beneficial in
a number of diseases including cancer, neurodegenerative diseases
and metabolic diseases [30–33]. All of the above mentioned
compounds have been documented to exert positive effects, however
to our knowledge, they have not been systematically screened in
OXPHOS deficient patient’s cells together in the same system.
The objectives of this research were two-fold; to develop an in
vitro system for the rapid screening of multiple compounds using a
small amount of fibroblasts from individual patients and to identify
compounds with a therapeutic potential for mitochondrial
complex I deficiency.
Materials and Methods
Subjects
Fibroblasts previously derived (with informed consent, approved
by the IRB), from six patients with mitochondrial respiratory chain
complex I (CI) deficiency, were included in the study. Most of
these patients have been previously described and all harbored
known mutations in different nuclear encoded complex I subunits:
NDUFS2[34,8]. NDUFS4 or assembly factors; C6ORF66 (NDU-
FAF4)[35], C20ORF7[36], FOXRED1 [37,8] B17.2.L (NDU-
FA12L)[38]. Their clinical and biochemical data are briefly
summarized in Table 1.
Tissue cultures
Fibroblasts were maintained in DMEM (Biological Industries,
Kibbutz Beit Haemek, Israel) medium containing 4.5 g glucose
per liter and supplemented with 10% fetal calf serum, 50 mg/ml
uridine, and 110 mg/ml pyruvate (GLU, permissive medium) at
37uC, 5%CO2.
For assessment of various compounds, 3610
3 cells/100 ml were
seeded in triplicate on three identical 96 well microtiter plates. The
following day, the medium was removed, the wells were washed
once with phosphate buffered saline (PBS) and replaced with
100 ml GLU medium or a restrictive glucose-free DMEM medium
(Biological Industries, Kibbutz Beit Haemek, Israel) supplemented
with 10% dialyzed fetal calf serum and 5 mM galactose (GAL)
with or without additives as follows: 0.5 mM AICAR (Tocris,
Bioscience, Bristol UK); 50 mM Genistein (GENI) (Cayman
Chemicals Ann Arbor MI USA; 100 mM, Bezafibrate (BEZA);
10 mM Oltipraz (OLTIP); 5uM Resveratrol (RSV); 10 uM
Epigallocatechin gallate (EGCG)(Sigma-Aldrich, Steinheim, Ger-
many) or grape seed extract (GSE) (Ttianjin Jianfeng Natural
Products, China). 72h post-treatment the tissue cultures were
analyzed for growth, reactive oxygen species (ROS) and ATP.
(Biological Industries, Kibbutz Beit Haemek, Israel).
Assays
Cell growth was measured by a colorimetric method based on
the staining of basophilic cellular compounds (mainly nucleic
acids, independent on redox status) with methylene blue at
A620nm, as modified by Jones et al [39]. For the evaluation
methylene blue assay (MB) control cells were serially diluted in
GLU medium, seeded in six wells. After 48h triplicate wells were
measured by MB and triplicate wells were subjected to viable
count by trypan blue. For evaluation of time course, 3610
3
control cell and cells from a patient were seeded in GLU
medium. The following day the medium was replaced either with
fresh GLU or GAL. The amount of cells was quantified by MB
after 24 h, 48 h, 72 h and 144 h (medium was replaced with
fresh after 72 h).
The intracellular ROS production was measured using 29,79-
dichlorodihydrofluorescein diacetate (DCF) (Biotium Harvard CA
USA)[40]. Briefly, growth medium was removed and replaced by
100ul/well of 10 mM DCF in PBS-Ca
2+ Mg
2+ (PBS containing
0.9 mM calcium chloride and 0.5 mM magnesium chloride) and
the plates were incubated for 20 min at 37uC, 5%CO2. After
removal of DCF, the ROS production was monitored for 20
minutes in 100ul PBS-Ca
2+ Mg
2+ at lex 485 nm and lem 520 nm.
ATP content was measured by luciferin-luciferase using the
ATPliteH luminescence assay system according to the manufac-
turer’s instruction (Perkin Elmer Waltham MA, USA).
Luminescence, fluorescence and absorbance measurements
were performed with a Synergy HT microplate reader (Bio-Tek
instruments, Vinoosky VT, USA).
Relative fluorescence units (RFU) and relative luminescence
units (RLU) were calculated by normalizing to growth as
measured by MB in parallel wells for each separate experiment.
The mean of all experiments was calculated and compared to that
of GAL without additive (containing vehicle only). All experiments
were performed in triplicate wells on at least two separate
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tailed student’s t-test. Data were also visualized using the
matrix2png software [41]. http://www.bioinformatics.ubc.ca/
matrix2png/.
Fluorescence microscopy
Fibroblasts, were seeded at 3.5610
4 cells/ml in GLU medium.
The following day the medium was replaced with GLU, GAL or
GAL containing 0.5 mM AICAR for 72hrs. For assessment of
Table 1. Patient data.
patient/
mutated gene C20ORF7 NDUFS2 NDUFS4
C6ORF66
(NDUFAF4) FOXRED1 B17.2L (NDUFA12L)
age of onset 1 year 6 months 3 months birth 4 months 8 months
clinical details Leigh’s
syndrome,
mild lactic
acidosis, died
at 6years
optic atrophy, hypo
dense basal ganglia,
cardio-myopathy,
severe lactic acidosis,
died at 2years
lactic acidosis,
seizures
encephalo-myopathy,
severe lactic acidosis,
died at 2 months
Micro-cephaly,
encephalo-pathy,
lactic- acidosis
hypotonia, motor delay,
horizontal nystagmus,
bilateral optic atrophy,
abnormal MRI, mild
lactic acidosis
residual muscle
enzymatic
activities
CI 54% CIV 38%
CII,III within
normal range
CI 17% C II-V
within normal
range
CI 25% C II-V
within normal
range
CI 14% C II-V within
normal range
CI 7% C II-V within
normal range
CI 24% C II-V within
normal range
reference 36 34,11 unpublished 35,12 37 37,13
doi:10.1371/journal.pone.0026883.t001
Figue 1. Measurement of growth, ROS and ATP in control and patient fibroblasts. Fibroblast from control and patient (NDUFS2) were
grown in microtiter wells in GLU, GAL or GAL supplemented with AICAR. The amount of control cells, measured by methylene blue (MB) at A620 was
compared to viable count by trypan blue at 72h (A). Growth of control and patient cells was measured at 24,48,72h and 144h by MB at A620 (B,C).
Growth with AICAR was assessed at 72h (C). ROS measured by DCF at 72h is expressed as relative fluorescent units (RFU) divided by the amount of
cells measured by MB at A620 (D). ATP was measured at 72h by luciferin-luciferase is expressed as relative luminescence units (RLU) divided by the
amount of cells measured by MB at A620 (E). Values are presented as mean of triplicates +/- standard deviation. *p,0.05.
doi:10.1371/journal.pone.0026883.g005
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bottom tissue culture, plates and incubated with 200 nM Mito-
Tracker Green FM (MTG) and 50 nM tetramethylrhodamine ethyl
ester (TMRE) (Molecular Probes Eugene, Oregon USA), for 90 and
45minutesrespectively at37uC,5%CO2 [42].Forphospho-AMPK
(pAMPK) immunocytochemistry and Mitotracker stain, cells were
grown on fibronectin coated coverslips and incubated with 1.5 mM
MitoTracker Red CM-H2XRos (MTR, Molecular Probes Eugene,
Oregon USA) for 45minutes at 37uC, 5%CO2, chased for 30
minutes with the respective growth medium, fixed with 4%
paraformaldehyde in PBS, permeabilized with 0.25% Triton X-
100, stained with 1:75 Phospho-AMPKa-(Thr172) primary anti-
body (Cell Signalling Technology Inc.Denver MA,USA) and
subsequently, with Dylight 488 conjugated anti rabbit secondary
antibody (JacksonThermoScientific, Rockford IL,USA). Cells were
visualized by fluorescent confocal microscopy (1064). Image
analysis was done with MetaMorph image analysis software. All
micrographs in a series were taken under the same conditions.
Oxygen consumption
Oxygen consumption rate (OCR) was measured using an XF24
extracellular flux analyzer (Seahorse Biosciences, North Bill-
eric,MA,USA). Fibroblast were seeded at 12- 14610
3 cells/well
in 300 ml in GLU medium on an XF 24 well plate at 37uC,
5%CO2. The following day the medium was replaced with GLU,
GAL or GAL containing 0.5 mM AICAR. After 72hrs the growth
medium was changed to 500 ml unbuffered DMEM medium with
the same constituents as above (GLU, GAL or GAL with AICAR)
and incubated at 37uC for 1h for equilibration before the
measurements. After 10 minutes of OCR baseline measurements,
50 ml carbonylcyanide-3-chlorophenylhydrazone (CCCP) was
injected to reach a working concentration of 20 mM and the
maximal OCR was measured. Background OCR was measured
after injection of rotenone and antimycin to a final concentration
of 5 mM each. After the experiment, cell content was estimated by
MB and OCR was calculated as OCR minus background divided
by MB.
Figure 2. The effect of various compounds on growth, ROS and ATP in control and patient fibroblasts. Fibroblast from three separate
controls and seven patients (C20ORF7,NDUFS2,NDUFS4,C6ORF66, FOXRED1 and B17.2L) were grown in microtiter wells in GLU or GAL medium or in
GAL medium, supplemented with one of eight various compounds (BEZA,AICAR,OLTI,SBP,RZV,GENI,EGCG,GSI) in GAL for 72hrs. Growth was assessed
by MB (A). ROS was measured by DCF and normalized to MB (B). ATP was measured by luciferin-luciferase and normalized to MB (C). Values (A-C) are
presented as relative values graphically presented as heatmaps representing the mean of triplicates performed on at least 2 separate occasions.
Growth in GAL without additives was set as the value of 1(black). Values , 1 are presented in increasingly green and values .1 in increasingly red. All
parameters are summarized in (D) and evaluated as a significantly positive (+), negative (2) or nonsignificant (ns) effect. Increased values for growth
and ATP were regarded as positive while negative for increased ROS. Positive only is shaded in red, negative only in green, nonsignificant in dark grey
and mixed responses in gray.
doi:10.1371/journal.pone.0026883.g001
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All patients presented in infancy, were severely affected and
diagnosed with isolated CI deficiency in muscle, with the
exception of patient C20ORF7 who had a combined partial
deficiency of both CI and CIV. All patients were molecularly
defined with mutations either in a nuclear encoded CI subunit or
in a CI assembly factor (Table 1). Fibroblasts from these patients
were initially assessed for growth, ROS production and ATP
content. Preliminary experiments demonstrated that 3610
3 cells/
well was sufficient to obtain clear readings and reproducible results
(Fig. 1A). As it was not possible to measure all parameters in the
same well, 3 identical plates treated in parallel were measured in
each experiment. Still it was possible to screen ten variables in
triplicate wells using less than 3610
5 cells (less than a T25
confluent flask). In order to relate values to cell content, we initially
evaluated the MB assay and compared those values to values
obtained by viable counts. There was a linear relationship between
the number of cells and methylene blue absorption (Fig. 1A). As
MB staining is much more feasible to perform than viable
counting of hundreds of microtiter wells, we therefore continued to
evaluate growth by the MB assay. Accordingly, all RFU and RLU
values were normalized to MB in order to compare values per cell
content. To establish a suitable time frame for the experiments we
compared the time course of growth in GLU and GAL. While
patient’s cell growth was comparable to control cells in GLU
media, impaired growth of patient’s cells in GAL media was
evident after 72h (Fig. 1B). Therefore, 72h was chosen as the
optimal time frame for examining compounds.
A typical experiment with control and patient fibroblasts is
depicted in Fig. 1C–D. Since it is difficult to present and summa-
rize a large number (1000,) of measurements, the summary of all
data are depicted as a heatmaps in Fig. 2 A–C. (The values on
GAL were set at 1 in the middle of the scale (black). Values less
than 1 were increasingly green and higher then 1 increasingly red)
The growth in GAL medium relative to GLU was slightly
decreased in control fibroblasts while growth was markedly
decreased in all patients cells (Fig. 2A). These results were
anticipated, as GAL medium is devoid of substrates for glycolysis
and therefore growth is highly dependent on the oxidation of fatty
acids (derived from FCS) by intact OXPHOS for energy
production [43]. Intracellular ROS production was generally
increased in GAL medium. The increase was evident in one
control and four of the patients (Fig. 2B). In patient NDUFS2 the
ratio was reversed, presumably because of the severe growth defect
in GAL (Fig. 1 B). This is also be the reason for the very low ATP
Figure 3. The effect of AICAR on mitochondrial content and Dy. Control 1 and an NDUFS2 patient’s fibroblasts were grown in GLU or GAL
medium and in GAL supplemented with 0.5 mM AICAR (GAL+AICAR) for 72 hrs. Cells were then incubated with TMRE (red) and Mitrotracker green
(green) and examined by confocal fluorescent microscopy. A: depicts a representative micrograph TMRE stain in red and MTG stain in green. The
graphs represent green intensity per cell (B) and red:green ratio (C), +/2 standard deviation (*p,0.05). All micrographs were taken under the same
conditions.
doi:10.1371/journal.pone.0026883.g002
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higher ATP content in GAL medium, reflecting the higher
efficiency of ATP production by OXPHOS than by glycolysis.
This was not the case for four of the six patients and reflects the CI
defect. Notably cells with a high ATP content in GAL were
derived from controls or patients C2ORF7 and NDUFS4 with a
relatively high residual CI activity in muscle (Table 1, Fig. 2C).
Next, the effect of various compounds was examined. The
compounds tested were polyphenols, and other compounds with
reported effects on ROS production and mitochondrial biogenesis.
Untreated cells in the presence of vehicle (DMSO), cells grown in
GAL and control cells were included in each experiment. It should
be noted that the examination of the effect of different compounds
required a prior set of experiments initially based on data available
from the literature, in order to optimize conditions with respect to
medium and concentration. As these experiments required larger
quantities of cells, they were performed in normal cells and in
some of the patient’s cells. From the preliminary data, we
concluded that the effect of additives was best demonstrated under
stressful conditions i.e in GAL medium compared to growth with
vehicle only in the same medium (Fig. 1B). The effect of each
compound on each cell on each of the above parameter is
presented in Fig. 2A–C. Many compounds either lacked any effect
or had a beneficial effect on growth. For example, bezafibrate
increased growth in C20ORF7 approaching that in GLU
medium. On the contrary, genistein, EGCG and grape seed
extract had a negative effect on growth. Therefore, the
investigation of these compounds was not continued in the
remaining cells (Fig. 2A). Intracellular ROS production was also
favorably affected by many compounds, although mostly by
bezafibrate and AICAR. The only compound with an overall
negative effect on ROS was sodiumphenylbutyrate (Fig. 2B).
AICAR exerted a positive effect on ATP content in four of the six
patient cells and one control cell line. Other cells were not affected
with the exception of the negative effect on NDUFS4 (Fig. 1C,
Fig. 2C).
In order to create a simplified overview, we rated a compound
as beneficial when it increased growth, ATP and decreased ROS
compared to the values on GAL. The evaluation was designated
with a plus sign for each favorable parameter while a negative
effect was designated with a minus sign. When no parameter was
significantly altered by a compound it was designated non
significant (ns). Mixed effects were designated plus/minus
(Fig. 2D). To summarize, AICAR was the most favorable
compound with positive effects on several parameters in five out
of six patient cells. Bezafibrate was also beneficial to two patient’
cells but to a lesser extent. Interestingly, Otipraz had a beneficial
effect on half the patient’s. Although sodium phenylbutyrate
slightly increased ROS in some cells, the overall score was positive
in fifty percent of the patients (Fig. 2D). No positive but many
mixed and some negative effects were observed with resveratrol,
EGCG and grapeseed extract. The effect of genistein was unclear
since it had a positive effect on only FOXRED1 cells while
negatively affected the control.
In order to further investigate the effect of AICAR we
conducted an extended study of a representative cell (NDUFS2)
to include the evaluation of mitochondrial content and mitochon-
drial Dy by fluorescence microscopy and oxygen consumption
(Figs. 3 and 4). Mitochondrial content estimated by MTG was
found slightly but significantly increased in both control and
patients cells in GAL medium. AICAR induced a clear increase in
mitochondrial content only in the patient’s cells (Fig. 3A and B).
The alteration of TMRE stain relative to mitochondrial content in
the presence of AICAR was minor and not significant, indicating
that Dy was not substantially affected (Fig. 3A and C). While
uncoupled oxygen consumption was increased in GAL medium,
AICAR had no significant effect (Fig. 4A and B) although the basal
uncoupled OCR was somewhat, not significantly relative to basal
OCR in the patient’s cells (Fig. 4B).
To examine to the downstream effect of AICAR, we performed
immunostaining with an antibody towards Thr172 phosphorylat-
ed AMPK (pAMPK) while co-staining with MTR (Fig. 5A–C).
Figure 4. Oxygen consumption. Control 1 (A) and NDUFS2 patient’s (B) fibroblasts were grown in GLU or GAL medium and in GAL supplemented
with 0.5 mM AICAR (GAL+AICAR) for 72 hrs. Media were changed to unbuffered media and oxygen consumption rates (OCR) were measured by an
XF24 instrument. Basal OCR was measured (basal) before the addition of uncoupler and maximal rate (CCCP) after. The results are presented as rates
subtracted by non mitochondrial oxygen consumption (in the presence of rotenone and antimycin) and normalized to cell amount measured by
methylene blue (MB)at A620, +/2 standard deviation. *p,0.05.
doi:10.1371/journal.pone.0026883.g003
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in NDUFS2 cells grown on GLU (Fig. 5A and B). AICAR
supplementation caused a marked and significant increase of
pAMPK in the patients cells. Mitotracker stain was increased in
patient’s cells on GAL but approached control values in the
presence of AICAR (Fig. 5A and C).
Discussion
The search for therapeutic agents for mitochondrial complex I
deficiency and OXPHOS defects in general, is seriously hampered
by the lack of a standardized model system for evaluating
treatment. Many studies focused on small groups of patients
simultaneously treated with several agents leading to difficulties in
interpreting data and patient responses to therapy in vivo.
Documented in vitro assays usually focus on a specific compound
or a specific parameter using a relatively large sample size (11–
13,17).
We developed an accessible and relatively simple system in 96
well plates assessing a number of different parameters by the use of
one instrument. This enabled us screen multiple compounds on a
small amount of fibroblasts simultaneously while measuring a
number of different parameters. The small sample size allowed the
use of primary cells which is advantageous not only for practical
reasons but also because immortalized cells frequently do not
retain their original phenotype and thus respond differently than
primary cells (personal experience).
The fibroblasts for this study were chosen to represent CI
deficiency, the most common OXPHOS defect. The cells were
derived from patients with different CI defects, in order to assess
individual responses to different compounds. Indeed the responses
differed in some instances between the patients. This is exemplified
by bezafibrate which was beneficial for NDUFS2 ATP content but
not for C20ORF7, emphasizing the need to evaluate compounds
on an individual basis. Individual evaluation is especially
important when attempting to treat disorders where the
mitochondrial function is already a priori compromised. The
necessity to measure different parameters was evident when
observing the effect of the various polyphenolic cytochemicals
(resveraterol, EGCG, grape seed extract and geneticin) included in
the study. Generally they decreased ROS formation which is
advantageous, but concomitantly decreased growth and ATP
content. Although some of these results contradict studies
reporting positive effects previously mentioned in the introduction,
Figure 5. The effect of AICAR on pAMPK and mitotracker red stain in control and patient fibroblasts. Control and patient fibroblasts
were grown on coverslips in GLU or GAL medium and in GAL supplemented with 0.5 mM AICAR (GAL+AICAR) for 72 hrs. Cells were than incubated
with mitotracker red (MTR), fixed, stained with anti pAMPK antibodies and visualized by fluorescent (pAMPK) secondary antibodies. The coverslips
were examined by confocal fluorescent microscopy (10640). A: depicts a representative migrograph of pAMPK stain in green and MTR stain in red.
The graphs represent green intensity per cell (B) and red intensity per cell (C) +/2 standard deviation (*p,0.05). All micrographs were taken under
the same conditions.
doi:10.1371/journal.pone.0026883.g004
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polyphenols can induce cancer cell death though mitochondrial
membrane depolarization and apoptosis [44,45]. On the other
hand, AICAR was found to be the most promising compound with
no detected negative effect and an overall positive score in most of
the patient’s cells. The positive effect on mitochondrial biogenesis
was also clearly visible by the MTG stain while the Dy was not
affected. Immunocytochemistry also supported activation of
AMPK. Remarkably AICAR has been given intravenously to
humans in clinical trials for the treatment of hyperinsulinemia
[46]. Recently AICAR was also reported to be favorable in
cytochrome c oxidase deficiency [47,48].
Apparently there is a discrepancy between the mixed effect of
resveratrol and the positive effect of AICAR since they both
activate the same SIRT1, PGC1a axis pathway [18,24,49]. The
underlying mechanism for this inconsistency remains unclear and
requires further thorough investigation. Nevertheless, we suggest
that the positive effects of resveratrol on patients cells might be
masked by some additional negative effects. Notably, resveratrol
was reported to inhibit the mitochondrial FoF1 ATPsynthase
(complex V) and oxygen consumption while depleting ATP
content [50,51]. In fact, resveratrol alone is suggested to act as
an anticancer compound by targeting mitochondria through the
activation of pro-apoptotic pathways [52]. It is therefore
conceivable that resveratrol might exert a negative effect on some
parameters on some individual patient’s cells with an a priori
mitochondrial dysfunction. Apart from AICAR, oltipraz and
bezafibrate disclosed a general positive effect, but to a lesser extent.
Sodium phenylbutyrate increased ATP but also caused a slight
increase of ROS and therefore the use of this compound in
OXPHOS defects could be questionable.
We detected only a partial correlation between individual
responses in fibroblasts and residual enzymatic complex I activity
in muscle, genotype or clinical presentation (Table and Fig. 2).
Moreover, the clinical correlation between fibroblasts responses
and patients response to treatment has only been proved in a few
instances and further correlation studies are warranted [11,17].
Nevertheless patient’s fibroblasts provide an accessible tissue for
testing individual responses to additives and drugs [48].
Taken together, we present an accessible and relative simple
system using a small amount of patient’s fibroblasts for screening
potential treatments in OXPHOS defects. This enables the
screening to be performed on an individual basis while measuring
a number of different parameters which are not limited to the
measurement of a specific respiratory chain complex. Conse-
quently the system has a wide applicability, and could be used for
other defined and undefined OXPHOS defects. The authors are
aware that this system is suitable for preliminary screening only,
and that the results will have to be verified by precise investigation
of additional parameters and mechanisms by other methods
measuring OXPHOS by enzymatic assays and expression analysis
on the protein and mRNA levels. Nonetheless these assays are
more complex and require a larger number of cells making them
much less applicable for screening purposes. We propose that
rapid preliminary screening of potential therapeutic compounds in
individual patient’s fibroblasts could direct and advance person-
alized medical treatment.
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